12/25/2025

Janusmed kön och genus

Janusmed kön och genus – Dupilumab

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Dupilimab

Dupilimab

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Dupixent (dupilumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-12-01, cited 2025-12-12]

  2. Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. Front Pediatr. 2019;7:246.

  3. Chowdhury NU, Guntur VP, Newcomb DC, Wechsler ME. Sex and gender in asthma. Eur Respir Rev. 2021;30(162):.

  4. Johansson EK, Bergström A, Kull I, Melén E, Jonsson M, Lundin S et al. Prevalence and characteristics of atopic dermatitis among young adult females and males-report from the Swedish population-based study BAMSE. J Eur Acad Dermatol Venereol. 2022;36(5):698-704.

  5. Tuttle KL, Forman J, Beck LA. Novel systemic treatments in atopic dermatitis: Are there sex differences?. Int J Womens Dermatol. 2021;7:606-614.

  6. Tayefi M, Bradley M, Neijber A, Fastberg A, Ceynowa D, Eriksson M. Chronic Urticaria: A Swedish Registry-based Cohort Study on Population, Comorbidities and Treatment Characteristics. Acta Derm Venereol. 2022;102:adv00624.

  7. Roberts SE, Morrison-Rees S, Thapar N, Williams JG. Incidence and prevalence of eosinophilic oesophagitis across Europe: A systematic review and meta-analysis. United European Gastroenterol J. 2024;12(1):89-102.

  8. Allin KH, Poulsen G, Melgaard D, Frandsen LT, Jess T, Krarup AL. Eosinophilic oesophagitis in Denmark: Population-based incidence and prevalence in a nationwide study from 2008 to 2018. United European Gastroenterol J. 2022;10(7):640-650.

  9. Dupixnet (dupilumab). EPAR - Public Assessment Report. European Medicines Agency (EMA) [updated 2024-04-09, cited 2025-11-17]

  10. Bult L, Thelen JC, Rauh SP, Veen JCCMI', Braunstahl GJ. Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study. Respir Med. 2024;231:107720.

  11. Chokevittaya P, Jirattikanwong N, Thongngarm T, Phinyo P, Wongsa C. Factors Associated With Dupilumab Response in Atopic Dermatitis: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2024;12(11):3044-3056.

  12. Yu L, Lian C, Li L, Li J, Zhang S. Predictors for the Efficacy of 4-Week Dupilumab Treatment in Atopic Dermatitis Patients. J Asthma Allergy. 2025;18:331-337.

  13. Wang Y, Jia R, Hu Q, Tao X, He Q, Luo G et al. Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a prospective real-world cohort study in China. Front Immunol. 2024;15:1419164.

  14. Leo F, Mastorino L, Fiasconaro CA, Accorinti M, Quaglino P, Ortoncelli M et al. Does Female Sex Correlate to Faster Responses of Dupilumab in Pediatric Patients with Moderate-To-Severe Atopic Dermatitis? A Real-Life Experience. Dermatitis. 2025;36(2):177-179.

  15. Xu Y, Li B, Wang W. Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China. Front Immunol. 2025;16:1644875.

  16. Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab. JAMA Dermatol. 2025;161(8):813-821.

  17. Sharif K, Omar M, Lahat A, Patt YS, Amital H, Zoabi G et al. Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4/IL13 blockade. Front Pharmacol. 2023;14:1271309.

  18. Mastorino L, Richiardi I, Gelato F, Cavaliere G, Quaglino P, Ortoncelli M et al. Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents. Expert Opin Biol Ther. 2024;24(8):863-868.

  19. Pezzolo E, Rossi M, Caroppo F, Bianchelli T, Belloni Fortina A, Giacchetti A et al. Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study. J Eur Acad Dermatol Venereol. 2023;37(6):e757-e759.

  20. Spekhorst LS, de Graaf M, Zuithoff NPA, van den Reek JMPA, Kamsteeg M, Boesjes CM et al. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry. JAMA Dermatol. 2022;158(9):1048-1056.

  21. Dal Bello G, Maurelli M, Schena D, Girolomoni G, Gisondi P. Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. Dermatol Ther. 2020;33(6):e13979.

  22. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. Dupixent (dupilumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-12-01, cited 2025-12-12]
  2. Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. Front Pediatr. 2019;7:246.
  3. Chowdhury NU, Guntur VP, Newcomb DC, Wechsler ME. Sex and gender in asthma. Eur Respir Rev. 2021;30(162):.
  4. Johansson EK, Bergström A, Kull I, Melén E, Jonsson M, Lundin S et al. Prevalence and characteristics of atopic dermatitis among young adult females and males-report from the Swedish population-based study BAMSE. J Eur Acad Dermatol Venereol. 2022;36(5):698-704.
  5. Tuttle KL, Forman J, Beck LA. Novel systemic treatments in atopic dermatitis: Are there sex differences?. Int J Womens Dermatol. 2021;7:606-614.
  6. Tayefi M, Bradley M, Neijber A, Fastberg A, Ceynowa D, Eriksson M. Chronic Urticaria: A Swedish Registry-based Cohort Study on Population, Comorbidities and Treatment Characteristics. Acta Derm Venereol. 2022;102:adv00624.
  7. Roberts SE, Morrison-Rees S, Thapar N, Williams JG. Incidence and prevalence of eosinophilic oesophagitis across Europe: A systematic review and meta-analysis. United European Gastroenterol J. 2024;12(1):89-102.
  8. Allin KH, Poulsen G, Melgaard D, Frandsen LT, Jess T, Krarup AL. Eosinophilic oesophagitis in Denmark: Population-based incidence and prevalence in a nationwide study from 2008 to 2018. United European Gastroenterol J. 2022;10(7):640-650.
  9. Dupixnet (dupilumab). EPAR - Public Assessment Report. European Medicines Agency (EMA) [updated 2024-04-09, cited 2025-11-17]
  10. Bult L, Thelen JC, Rauh SP, Veen JCCMI', Braunstahl GJ. Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study. Respir Med. 2024;231:107720.
  11. Chokevittaya P, Jirattikanwong N, Thongngarm T, Phinyo P, Wongsa C. Factors Associated With Dupilumab Response in Atopic Dermatitis: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2024;12(11):3044-3056.
  12. Yu L, Lian C, Li L, Li J, Zhang S. Predictors for the Efficacy of 4-Week Dupilumab Treatment in Atopic Dermatitis Patients. J Asthma Allergy. 2025;18:331-337.
  13. Wang Y, Jia R, Hu Q, Tao X, He Q, Luo G et al. Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a prospective real-world cohort study in China. Front Immunol. 2024;15:1419164.
  14. Leo F, Mastorino L, Fiasconaro CA, Accorinti M, Quaglino P, Ortoncelli M et al. Does Female Sex Correlate to Faster Responses of Dupilumab in Pediatric Patients with Moderate-To-Severe Atopic Dermatitis? A Real-Life Experience. Dermatitis. 2025;36(2):177-179.
  15. Xu Y, Li B, Wang W. Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China. Front Immunol. 2025;16:1644875.
  16. Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab. JAMA Dermatol. 2025;161(8):813-821.
  17. Sharif K, Omar M, Lahat A, Patt YS, Amital H, Zoabi G et al. Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4/IL13 blockade. Front Pharmacol. 2023;14:1271309.
  18. Mastorino L, Richiardi I, Gelato F, Cavaliere G, Quaglino P, Ortoncelli M et al. Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents. Expert Opin Biol Ther. 2024;24(8):863-868.
  19. Pezzolo E, Rossi M, Caroppo F, Bianchelli T, Belloni Fortina A, Giacchetti A et al. Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study. J Eur Acad Dermatol Venereol. 2023;37(6):e757-e759.
  20. Spekhorst LS, de Graaf M, Zuithoff NPA, van den Reek JMPA, Kamsteeg M, Boesjes CM et al. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry. JAMA Dermatol. 2022;158(9):1048-1056.
  21. Dal Bello G, Maurelli M, Schena D, Girolomoni G, Gisondi P. Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. Dermatol Ther. 2020;33(6):e13979.
  22. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]